Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:28:12 Source:healthViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
You may also like
- Ben Whishaw lights up the Croisette as he joins his co
- Autumn scenery across China
- Annual spring farming ceremony held in China's Tibet
- Carriers sanguine on travel season
- Hall of Fame outfielder Ken Griffey Jr. to lead Indianapolis 500 field in Corvette pace car
- Xinhua Commentary: For China and U.S., One's Success Is an Opportunity for the Other
- Martial arts enthusiasts found training class for local children
- More Chinese students experience unwarranted interrogation, harassment, deportation at U.S. border
- Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise